As of 2025-07-02, the Relative Valuation of Urogen Pharma Ltd (URGN) is (33.10) USD. This relative valuation is based on P/E multiples. With the latest stock price at 13.70 USD, the upside of Urogen Pharma Ltd based on Relative Valuation is -341.6%.
The range of the Relative Valuation is (14.71) - (50.14) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 4.7x - 16.7x | 10.7x |
| Forward P/E multiples | 4.9x - 17.8x | 11.4x |
| Fair Price | (14.71) - (50.14) | (33.10) |
| Upside | -207.4% - -466.0% | -341.6% |
| Date | P/E |
| 2025-07-01 | -4.47 |
| 2025-06-30 | -4.56 |
| 2025-06-27 | -4.49 |
| 2025-06-26 | -4.37 |
| 2025-06-25 | -4.57 |
| 2025-06-24 | -4.59 |
| 2025-06-23 | -4.76 |
| 2025-06-20 | -4.88 |
| 2025-06-18 | -4.95 |
| 2025-06-17 | -4.41 |
| 2025-06-16 | -4.78 |
| 2025-06-13 | -4.01 |
| 2025-06-12 | -3.69 |
| 2025-06-11 | -2.43 |
| 2025-06-10 | -2.35 |
| 2025-06-09 | -2.34 |
| 2025-06-06 | -2.45 |
| 2025-06-05 | -1.71 |
| 2025-06-04 | -1.64 |
| 2025-06-03 | -1.67 |
| 2025-06-02 | -1.61 |
| 2025-05-30 | -1.41 |
| 2025-05-29 | -1.32 |
| 2025-05-28 | -1.35 |
| 2025-05-27 | -1.31 |
| 2025-05-23 | -1.40 |
| 2025-05-22 | -1.36 |
| 2025-05-21 | -1.39 |
| 2025-05-20 | -2.51 |
| 2025-05-19 | -2.65 |
| 2025-05-16 | -2.43 |
| 2025-05-15 | -3.28 |
| 2025-05-14 | -3.29 |
| 2025-05-13 | -3.38 |
| 2025-05-12 | -3.71 |
| 2025-05-09 | -3.46 |
| 2025-05-08 | -3.55 |
| 2025-05-07 | -3.37 |
| 2025-05-06 | -3.23 |
| 2025-05-05 | -3.65 |
| 2025-05-02 | -3.83 |
| 2025-05-01 | -3.80 |
| 2025-04-30 | -3.88 |
| 2025-04-29 | -3.58 |
| 2025-04-28 | -3.75 |
| 2025-04-25 | -3.29 |
| 2025-04-24 | -3.37 |
| 2025-04-23 | -3.40 |
| 2025-04-22 | -3.35 |
| 2025-04-21 | -3.22 |